FDA delays decision on Risperdal Consta to treat bipolar disorder

02/10/2009 | Bloomberg · Forbes

Seeking more information, the FDA postponed its decision on the use of Johnson & Johnson's Risperdal Consta to treat frequent mood swings in patients with bipolar disorder. The product received FDA clearance in 2003 as a twice-a-month treatment for schizophrenia.

View Full Article in:

Bloomberg · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC